Our pipeline includes products selected based on scientific merit, unmet medical need, and the ability to rapidly achieve proof of concept in selected patient populations. These targeted interventions take advantage of the unique differences between cancer cells and normal cells. By disrupting the mechanisms that allow cancer to develop and grow, targeted treatments have the potential for improved patient outcomes and fewer side effects. Additionally, we emphasize the use of biomarkers and companion diagnostics to identify which patients are most likely to benefit based on tumor genetic signatures, protein expression patterns, and other key markers, thereby accelerating the establishment of proof of concept.
Through its unique business model, Triphase is actively working on the development of its proprietary drug products TRPH-222 and TRPH-395 as well as continuing to collaborate with Bristol-Myers Squibb on the development of marizomib.